{"id":"W4309184100","doi":"10.1001/jamaoncol.2022.5228","title":"Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors","year":2022,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Foundation Medicine; Genentech; Astellas Pharma; Incyte; National Center for Advancing Translational Sciences; Seagen; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Symphogen; GlaxoSmithKline; Amgen; Pfizer","keywords":"Medicine; Prostate cancer; Oncology; Internal medicine; Avelumab; Cancer; Lung cancer; Breast cancer; Immunogenicity; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Immunotherapy; Antigen; Immunology; Phases of clinical research; Chemotherapy; Clinical trial; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002135516,0.0004328489,0.001327317,0.0004762814,0.00008546004,0.00001509181,0.0002726853,0.0008825228,0.004030329],"category_scores_gemma":[0.00007917117,0.0003964938,0.0001325513,0.0004030155,0.0002111733,0.0001033838,0.0001261733,0.004193044,0.00009882074],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004796875,"about_ca_system_score_gemma":0.001663045,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006531122,"about_ca_topic_score_gemma":0.00004203977,"domain_scores_codex":[0.9968657,0.0002924101,0.0006695103,0.0007494724,0.0007162527,0.0007066612],"domain_scores_gemma":[0.9983276,0.0002373714,0.0005235491,0.0006334197,0.0001756221,0.0001024452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004936041,0.0003486706,0.005354909,0.0001777126,0.0001355143,0.003965983,0.0004384724,0.0001143773,0.00001871628,0.00001215241,0.974759,0.009738456],"study_design_scores_gemma":[0.02496895,0.005896143,0.01473311,0.0002570765,0.00006880415,0.0001452797,0.00005910091,0.00001529624,0.00004647605,0.00007202225,0.953338,0.0003997447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.154031,0.000306769,0.00003196989,0.8054116,0.002365041,0.003062458,0.0003672501,0.0002185019,0.0342054],"genre_scores_gemma":[0.03221844,0.00006208402,0.0007676162,0.9558852,0.00237994,0.001318009,0.003109216,0.000190147,0.004069345],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1504736,"threshold_uncertainty_score":0.9998487,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01410302039239859,"score_gpt":0.3020944315400396,"score_spread":0.287991411147641,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}